The occurrence of imatinib resistance has led to research on additional inhibitors of BCR-Abl, and the second-generation inhibitors (nilotinib and dasatinib) were recently approved for use in imatinib-resistant CML patients, in addition to front-line therapy [6,7]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.